NCT01255592

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.

Conditions

• Bronchiectasis
• Lung Disease
• Respiratory Diseases

Interventions

Type	Name	Description
DRUG	AZD5069	Oral dose bid
DRUG	Placebo	Oral dose bid

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2010-12-07
• Last updated: 2015-10-08
• Results posted: 2015-10-08

Locations

15 sites across 3 countries: Czechia, Poland, United Kingdom